2023
Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma
Olszewski A, Ollila T, Pelcovits A, Chorzalska A, Morgan J, McMahon J, Donnelly S, Huntington S, Matasar M, Reagan J, Milrod C, Dubielecka P. Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma. Blood 2023, 142: 1651. DOI: 10.1182/blood-2023-181418.Peer-Reviewed Original ResearchEnd of therapyCytokine release syndromeMarginal zone lymphomaT cellsComplete responsePD1 expressionNK cellsB cellsEffector memory T cellsCheckpoint inhibitor combinationsExpression of LAG3Immune cell changesB-cell depletionFirst-line therapyExpansion of TregsT cell exhaustionMemory T cellsPrior chemotherapy exposureImmune cell subsetsImmune cell compositionPeripheral blood samplesMulticolor flow cytometrySignificant increaseTreatment-induced changesExhausted phenotype
2019
Norovirus Changes Susceptibility to Type 1 Diabetes by Altering Intestinal Microbiota and Immune Cell Functions
Pearson JA, Tai N, Ekanayake-Alper DK, Peng J, Hu Y, Hager K, Compton S, Wong FS, Smith PC, Wen L. Norovirus Changes Susceptibility to Type 1 Diabetes by Altering Intestinal Microbiota and Immune Cell Functions. Frontiers In Immunology 2019, 10: 2654. PMID: 31798584, PMCID: PMC6863139, DOI: 10.3389/fimmu.2019.02654.Peer-Reviewed Original ResearchConceptsExpansion of TregsNOD miceT cellsMNV4 infectionMucosal immunityNon-obese diabetic (NOD) mouse modelGerm-free NOD miceFirmicutes/Bacteroidetes ratioProinflammatory T cellsRole of norovirusesTuft cell markersDevelopment of T1DInflammatory T cellsCommon enteric virusesB cell subsetsDiabetic mouse modelImmune cell functionType 1 diabetes susceptibilityEnteric virusesNaïve splenocytesT1D protectionTreg numbersImmunological changesMucosal antibodiesT1D development
2018
Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection
Tahvildari M, Inomata T, Amouzegar A, Dana R. Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection. Current Ophthalmology Reports 2018, 6: 266-274. PMID: 31807370, PMCID: PMC6894425, DOI: 10.1007/s40135-018-0191-2.Peer-Reviewed Original ResearchCorneal transplantationAllograft survivalGraft rejectionT cellsActivation of effector T cellsIncreased risk of graft rejectionPromote corneal allograft survivalRegulatory T-cell modulationInduction of immune toleranceRisk of graft rejectionTherapeutic approachesCorneal allograft survivalExpansion of TregsCorneal graft rejectionEffector T cellsRegulatory T cellsPromote transplant survivalAdaptive immune responsesHigh-risk allograftsModulation of cytokinesHost bedTargeting TregsImmune toleranceGraft survivalTregs
2009
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
Radojcic V, Bezak K, Skarica M, Pletneva M, Yoshimura K, Schulick R, Luznik L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunology, Immunotherapy 2009, 59: 137-148. PMID: 19590872, PMCID: PMC3103867, DOI: 10.1007/s00262-009-0734-3.Peer-Reviewed Original ResearchConceptsDendritic cell homeostasisAntitumor immunityT cellsLow-dose total body irradiationTumor antigen-specific T cellsAnti-CD25 monoclonal antibodyHematopoietic stem cell supportAntigen-specific T cellsUntreated tumor-bearing animalsTumor-infiltrating DCsExpansion of TregsRegulatory T cellsStem cell supportTotal body irradiationT cell responsesLess IL-10More IL-12Tumor-bearing animalsT cell eliminationCell homeostasisDC turnoverTreg depletionImmunotherapeutic strategiesIL-10Body irradiation
2007
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. Journal Of Clinical Investigation 2007, 117: 3857-3867. PMID: 18060033, PMCID: PMC2096456, DOI: 10.1172/jci32405.Peer-Reviewed Original ResearchConceptsB-cell depletionCell depletionB cellsNOD miceTherapeutic B cell depletionTransgenic NOD miceRegulatory B cellsLong-term remissionExpansion of TregsOnset of diabetesType 1 diabetesReverse diabetesClinical efficacyDiabetic miceAutoimmune diseasesFrank hyperglycemiaAntigen presentationT cellsHuman CD20DiabetesTherapeutic actionMiceClinical hyperglycemiaDiseasePotential mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply